Evidence map›Paper›PMID 32255255›Full record

ArticleMolecular oncology2020

Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics.

Max Krämer, Patrick S Plum, Oscar Velazquez Camacho, Kat Folz-Donahue, Martin Thelen, Isabel Garcia-Marquez, Christina Wölwer, Sören Büsker, Jana Wittig, Marek Franitza and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Review
  5. Article
  6. Article
  7. Role and mechanism of CD90Molecular medicine (Cambridge, Mass.) · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Max KrämerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Patrick S PlumInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-8165-4553
Oscar Velazquez CamachoInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Kat Folz-DonahueFACS & Imaging Core Facility, Max Planck Institute for Biology of Ageing, Cologne, Germany.
Martin ThelenDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-2785-9726
Isabel Garcia-MarquezCenter for Molecular Medicine Cologne, University of Cologne, Germany.
Christina WölwerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Sören BüskerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Jana WittigInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Marek FranitzaCologne Center for Genomics, University of Cologne, Germany.
Janine AltmüllerCologne Center for Genomics, University of Cologne, Germany.
Heike LöserInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0003-4555-1327
Hans SchlößerDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Reinhard BüttnerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Wolfgang SchröderDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Christiane J BrunsDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Hakan AlakusDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Alexander QuaasInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Seung-Hun ChonDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-8923-6428
Axel M HillmerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-3381-7266
University of Cologne · DEAgency for Science, Technology and Research · SGMax Planck Institute for Biology of Ageing · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell transcriptomics have revolutionized our understanding of the cell composition of tumors and allowed us to identify new subtypes of cells. Despite rapid technological advancements, single-cell analysis remains resource-intense hampering the scalability that is required to profile a sufficient number of samples for clinical associations. Therefore, more scalable approaches are needed to understand the contribution of individual cell types to the development and treatment response of solid tumors such as esophageal adenocarcinoma where comprehensive genomic studies have only led to a small number of targeted therapies. Due to the limited treatment options and late diagnosis, esophageal adenocarcinoma has a poor prognosis. Understanding the interaction between and dysfunction of individual cell populations provides an opportunity for the development of new interventions. In an attempt to address the technological and clinical needs, we developed a protocol for the separation of esophageal carcinoma tissue into leukocytes (CD45+), epithelial cells (EpCAM+), and fibroblasts (two out of PDGFRα, CD90, anti-fibroblast) by fluorescence-activated cell sorting and subsequent RNA sequencing. We confirm successful separation of the three cell populations by mapping their transcriptomic profiles to reference cell lineage expression data. Gene-level analysis further supports the isolation of individual cell populations with high expression of CD3, CD4, CD8, CD19, and CD20 for leukocytes, CDH1 and MUC1 for epithelial cells, and FAP, SMA, COL1A1, and COL3A1 for fibroblasts. As a proof of concept, we profiled tumor samples of nine patients and explored expression differences in the three cell populations between tumor and normal tissue. Interestingly, we found that angiogenesis-related genes were upregulated in fibroblasts isolated from tumors compared with normal tissue. Overall, we suggest our protocol as a complementary and more scalable approach compared with single-cell RNA sequencing to investigate associations between clinical parameters and transcriptomic alterations of specific cell populations in esophageal adenocarcinoma.

Indexed as

Single-Cell AnalysisAdenocarcinomaAgedAged, 80 and overBiomarkers, TumorEsophageal NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHumansMaleMiddle AgedMucous MembranePrincipal Component AnalysisTranscriptomeBiomarkers, Tumorcancer-associated fibroblastscell typesesophageal adenocarcinomatranscriptomicstumor microenvironment

Identifiers

PMID32255255
PMCPMC7266280
OpenAlexW3014706033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.